Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

DISEASE CHARACTERISTICS:

• Histologically confirmed hematologic malignancies:

  • Chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL)

    • Absolute lymphocytosis of > 5,000/μL

    • Lymphocytes must appear morphologically mature with < 55% prolymphocytes (CLL)

      • Patients with > 55% prolymphocytes are considered as having PLL
    • Lymphocyte phenotype with expression of CD20, CD19, and CD5 (CLL)

  • Non-Hodgkin lymphoma

    • Any WHO classification of histologic subtype
    • Core biopsies acceptable for primary diagnosis and immunophenotyping
    • Bone marrow biopsies as sole means of diagnosis not allowed for follicular lymphoma

  • Hodgkin lymphoma

    • Any WHO classification of histologic subtype
    • Core biopsies acceptable for primary diagnosis and immunophenotyping
    • Bone marrow biopsy is required

  • Multiple myeloma

    • Patients must have active disease requiring treatment (Durie-Salmon stage I-III)

  • Acute myeloid leukemia

    • Must have < 10% bone marrow blasts and no circulating blasts

  • Myelodysplastic syndrome (MDS)

    • MDS as define by WHO criteria
    • Must have < 10% marrow blasts

• Relapsed or progressive disease or myelodysplasia ≥ 6 months after prior high-dose chemotherapy with autologous hematopoietic cell support

  • Prior syngeneic transplantation allowed

• Healthy donor meeting one of the following criteria:

  • HLA-identical sibling (6/6)

    • Serologic typing for class I (A, B) and molecular typing for class II (DRB1) required

  • 8/8 matched-unrelated donor

    • Molecular identity at HLA A, B, C, and DRB1 by high-resolution typing required
  • No syngeneic donors

PATIENT CHARACTERISTICS:

• Creatinine clearance ≥ 40 mL/min
• Total bilirubin ≤ 2 mg/dL
• AST ≤ 3 times upper limit of normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• DLCO ≥ 40% with no symptomatic pulmonary disease
• LVEF ≥ 30% by MUGA or ECHO
• No uncontrolled diabetes mellitus or active serious infection
• No known hypersensitivity to E.coli-derived products
• No HIV infection

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• At least 4 weeks should elapse between prior standard cytotoxic chemotherapy, radiation therapy, or surgery and the planned start of the preparative regimen on day -7